Emergent BioSolutions (EBS) Research & Development (2011 - 2026)

Emergent BioSolutions' Research & Development history runs 16 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• On a quarterly basis, Research & Development fell 30.46% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $48.6 million, a 31.26% decrease from a year earlier, with the FY2025 full-year figure at $53.2 million, down 24.75% from the prior year.
• Research & Development slipped to $10.5 million in Q1 2026 per EBS's latest filing, from $12.1 million in the prior quarter.
• Across five years, Research & Development topped out at $49.8 million in Q2 2022 and bottomed at $9.1 million in Q4 2024.
• The 5-year median for Research & Development is $15.3 million (2023), against an average of $25.4 million.
• Across the five-year window, Research & Development slumped 69.05% in 2024 and soared 32.97% in 2025, its largest moves.
• Year by year, Research & Development stood at $47.0 million in 2022, then plunged by 37.45% to $29.4 million in 2023, then slumped by 69.05% to $9.1 million in 2024, then surged by 32.97% to $12.1 million in 2025, then decreased by 13.22% to $10.5 million in 2026.
• Per Business Quant, the three latest EBS Research & Development figures stand at $10.5 million (Q1 2026), $12.1 million (Q4 2025), and $13.5 million (Q3 2025).